Inquiry Basket
CAS No.: 159857-79-1
Cat No.: BADC-00708
Purity: 95%
4.5 
Val-cit-PAB-OH is a cleavable ADC linker commonly used in targeted therapies. It responds to lysosomal enzymes for selective payload activation in cancer cells.
Structure of 159857-79-1
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| 100 mg | $188 | In stock | |
| 5 g | $249 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Val-Cit-PAB-OH is a protease-cleavable ADC linker extensively used in antibody-drug conjugate design. It contains a valine-citrulline (Val-Cit) dipeptide sequence linked to a para-aminobenzyl (PAB) self-immolative spacer, providing controlled release of ADC cytotoxins upon enzymatic cleavage. This linker design is widely adopted in ADC linker design for oncology therapeutics, as it allows selective activation of the payload in lysosomal environments while maintaining stability in systemic circulation.
In ADC payload applications, the Val-Cit sequence serves as a substrate for cathepsin B and related proteases, ensuring that the cytotoxic ADC payload is released specifically within target tumor cells. The PAB self-immolative spacer transduces enzymatic cleavage into efficient payload release, preserving antibody-antigen binding functionality. This structure enables precise control over drug-to-antibody ratios (DAR), supporting reproducible and predictable pharmacokinetic properties of ADCs.
The chemical stability of Val-Cit-PAB-OH under physiological conditions prevents premature payload detachment in plasma, while its protease sensitivity ensures effective release in the tumor microenvironment. The linker is compatible with a broad range of ADC cytotoxins, including auristatins, maytansinoids, and other potent therapeutic payloads, providing versatility in ADC design and development.
Val-Cit-PAB-OH is widely applied in ADC construction and bioconjugation workflows where controlled payload release, linker stability, and precise antibody conjugation are critical. Its combination of protease-cleavable dipeptide, self-immolative PAB spacer, and chemical robustness supports the generation of high-performance antibody-drug conjugates with optimized therapeutic efficacy and tumor specificity.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01679 | Mal-PEG2-Val-Cit-PABA-PNP | 1345681-52-8 | |
| BADC-00929 | Fmoc-D-Val-Cit-PAB | 1350456-65-3 | |
| BADC-00849 | Acetylene-linker-Val-Cit-PABC-MMAE | 1411977-95-1 | |
| BADC-01448 | mDPR-Val-Cit-PAB-MMAE | 1491152-26-1 | |
| BADC-00958 | Amino-PEG4-Val-Cit-PAB-MMAE | 1492056-71-9 | |
| BADC-00968 | MC-Val-Cit-PAB | 159857-80-4 | |
| BADC-00364 | Fmoc-Val-Cit-PAB | 159858-22-7 | |
| BADC-01348 | Val-Cit-PAB-MMAE TFA salt | 1608127-32-7 | |
| BADC-01745 | MC-Val-Cit-PAB-NH-C2-NH-Boc | 1616727-22-0 | |
| BADC-00610 | Mc-Val-Cit-PAB-Cl | 1639351-92-0 |
What is Val-cit-PAB-OH?
Val-cit-PAB-OH is a dipeptide-based, lysosomal enzyme-cleavable linker widely used in ADCs. The Val-Cit moiety is recognized by cathepsin B, while the PAB-OH self-immolative group enables payload release upon enzymatic cleavage within target cells.
13/2/2022
We would like to know how Val-cit-PAB-OH influences ADC drug release.
Val-cit-PAB-OH ensures controlled intracellular release of cytotoxic payloads. The Val-Cit dipeptide is selectively cleaved by lysosomal enzymes, triggering the PAB-OH self-immolative spacer to release the attached drug efficiently and specifically.
5/7/2022
Could you kindly inform us what storage conditions are recommended for Val-cit-PAB-OH?
Val-cit-PAB-OH should be kept at -20°C, protected from moisture and light. Maintaining low-temperature storage and inert conditions prevents hydrolysis and degradation of the dipeptide and PAB-OH moiety.
2/8/2019
Good morning! Could you please confirm if BOC Sciences provides supporting documentation for Val-cit-PAB-OH?
Yes, supporting documentation such as CoA, NMR, and LC-MS data are available. These files confirm the chemical identity, functional group integrity, and suitability for ADC conjugation and downstream applications.
15/8/2022
Good morning! What analytical techniques do you recommend for Val-cit-PAB-OH?
Structural verification and functional assessment of Val-cit-PAB-OH are typically conducted using NMR spectroscopy, HPLC, and LC-MS to ensure quality and readiness for bioconjugation.
22/2/2019
— Dr. Olivia Brown, Senior Researcher (UK)
Val-cit-PAB-OH delivered excellent performance in our ADC linker synthesis. Purity and handling were ideal.
2/8/2019
— Mr. David Wilson, Chemistry Scientist (USA)
Batch-to-batch consistency of Val-cit-PAB-OH allowed seamless integration into our ADC pipeline.
22/2/2019
— Dr. Michael Carter, ADC Researcher (USA)
Val-cit-PAB-OH supplied by BOC Sciences demonstrated excellent purity and stability. It performed reliably in our ADC linker synthesis, ensuring reproducible results.
15/8/2022
— Dr. Michael Carter, ADC Researcher (USA)
Val-cit-PAB-OH supplied by BOC Sciences demonstrated excellent purity and stability. It performed reliably in our ADC linker synthesis, supporting reproducible results.
13/2/2022
— Dr. Mark Taylor, Bioconjugation Specialist (Canada)
Documentation and QC reports for Val-cit-PAB-OH were thorough, aiding regulatory submissions.
— Dr. Isabella Lee, Senior Scientist (USA)
The technical team provided guidance that optimized Val-cit-PAB-OH conjugation, improving ADC yield.
5/7/2022
Val-cit-PAB-OH
Required fields are marked with *
Val-cit-PAB-OH
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
